We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Open-Label Treatment Extension of Protocol MNTX 302

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01367613
Recruitment Status : Completed
First Posted : June 7, 2011
Last Update Posted : November 27, 2019
Information provided by:
Bausch Health Americas, Inc.

Brief Summary:
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.

Condition or disease Intervention/treatment Phase
Terminal Illness Drug: SC Methylnaltrexone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Three-Month Open-Label Treatment Extension of Protocol MNTX 302
Study Start Date : March 2004
Actual Primary Completion Date : January 2006
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: SC Methylnaltrexone

Primary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: 3 months ]
    To provide access to treatment with MNTX, administered SC, to patients who completed Progenics' Protocol MNTX 302

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be enrolled and consented within 28 days of the end of study visit of MNTX 302 and 14 or more days from first dose of study drug in MNTX 302.
  2. Negative pregnancy test
  3. Stable vital signs

Exclusion Criteria:

  1. Women who are pregnant and/or nursing
  2. Received any investigational product, other than MNTX, in the past 30 days
  3. Evidence of fecal impaction
  4. Clinically significant active diverticular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01367613

Layout table for location information
United States, New York
Progenics Pharmaceuticals, Inc.
Tarrytown, New York, United States, 10591
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for investigator information
Study Director: Tage Ramakrishna, MD Progenics Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Tage Ramakrishna, M.D., Progenics Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01367613    
Other Study ID Numbers: MNTX 302EXT
First Posted: June 7, 2011    Key Record Dates
Last Update Posted: November 27, 2019
Last Verified: November 2019
Keywords provided by Bausch Health Americas, Inc.:
Advanced medical illness
Additional relevant MeSH terms:
Layout table for MeSH terms
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents